Among patients with a confirmed diagnosis of CAD who underwent PCI, 97.9% were discharged on aspirin, 94.7% on second antiplatelet therapy (ticagrelor or clopidogrel), 90% on a β-blocker, 57% on an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) (71% with reduced EF), and 92% on a statin (Figure 2). Here, ACE is linked to coronary artery disorder.